Insmed, Inc. $INSM Shares Acquired by WCM Investment Management LLC

Key Points

• WCM Investment Management LLC increased its holdings in Insmed, Inc. by 6.7% in Q2, acquiring a total of 153,986 shares worth approximately $15.3 million.
• Insmed's recent earnings report revealed a loss of $1.70 per share, which was below the consensus estimate of $1.30, although its revenue increased by 18.9% year-over-year.
• Analysts maintain a consensus rating of "Moderate Buy" for Insmed, with price targets ranging from $130 to $180, indicating strong growth potential.

WCM Investment Management LLC lifted its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 6.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 153,986 shares of the biopharmaceutical company's stock after buying an additional 9,607 shares during the period. WCM Investment Management LLC owned approximately 0.08% of Insmed worth $15,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the stock. M&T Bank Corp boosted its position in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 147 shares during the period. ORG Partners LLC boosted its position in Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 196 shares during the period. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the period. Nisa Investment Advisors LLC boosted its position in Insmed by 6.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after buying an additional 228 shares during the period. Finally, Hilltop National Bank purchased a new position in Insmed in the 2nd quarter valued at approximately $28,000.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $163.19 on Friday. The company's fifty day moving average price is $142.26 and its 200 day moving average price is $104.19. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $166.44. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm has a market capitalization of $34.50 billion, a P/E ratio of -28.58 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the prior year, the business earned ($1.94) earnings per share. Insmed's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on INSM. Mizuho raised their price target on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Evercore ISI reaffirmed an "outperform" rating and set a $180.00 price objective on shares of Insmed in a research report on Wednesday, October 1st. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. William Blair assumed coverage on shares of Insmed in a research report on Wednesday, August 20th. They set an "outperform" rating for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $152.88.

Insider Activity

In related news, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares in the company, valued at $30,035,841.60. This trade represents a 2.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 211,057 shares of company stock worth $27,438,126 over the last three months. Company insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.